NeurogesX Inc. has entered into a $40 million royalty financing agreement with Cowen Healthcare Royalty Partners for the Qutenza patch, a dermal delivery system containing prescription strength capsaicin. Cowen Royalty can receive all of NeurogesX's royalties and sales milestones under the company's agreement with Astellas Pharma Europe, but NeurogesX retains economics related to U.S. sales. Release